Document is current
Any future updates will be listed below
-
Authors
Shigematsu, Hideo https://orcid.org/0000-0001-9393-9655
Fujisawa, Tomomi
Hara, Fumikata
Iwata, Hiroji
Ishiba, Toshiyuki
Ozaki, Yukinori
Sakai, Takehiko
Sagara, Yasuaki
Shimomura, Akihiko
Sudo, Kazuki
Terata, Kaori
Naito, Yoichi
Nozawa, Kazuki
Sasaki, Keita
Mitome, Noriko
Sadachi, Ryo
Shibata, Taro
Shien, Tadahiko
-
Funding
Funding for this research was provided by:
National Cancer Center (29-A-3 2020-J-3 2023-J-03)
japan agency for medical research and development (JP23ck0106846h0001)
Hiroshima University
- License Information
-
More Information
Article History
Received: 25 November 2025
Accepted: 8 January 2026
First Online: 22 January 2026
Declarations
:
: Hideo Shigematsu has received honoraria for lectures and chairing sessions organized by Daiichi Sankyo, Eisai, Chugai Pharmaceutical, Kyowa Kirin, Eli Lilly, Pfizer, Taiho Pharmaceutical, AstraZeneca, and MSD. Fumikata Hara has received honoraria for lectures and presentations from Pfizer, Kyowa Kirin, Eli Lilly, Chugai Pharmaceutical, Daiichi Sankyo, MSD, and Gilead Sciences. Hiroji Iwata has received grants to his institution from Chugai Pharmaceutical, Daiichi Sankyo, and AstraZeneca; and has received consulting fees and honoraria for lectures and educational events from Daiichi Sankyo, Chugai Pharmaceutical, AstraZeneca, Eli Lilly, MSD, Pfizer, and Gilead Sciences. Yukinori Ozaki has received honoraria from Pfizer, Daiichi Sankyo, Eli Lilly, and Chugai Pharmaceutical. Yasuaki Sagara has received honoraria for lectures and presentations from Pfizer, AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly, Chugai Pharmaceutical, MSD, Nippon Kayaku, Kyowa Kirin, and Sysmex. Akihiko Shimomura has received research grants from Daiichi Sankyo, Pfizer, AstraZeneca, Gilead Sciences, Eisai, and MSD; and honoraria from AstraZeneca, Daiichi Sankyo, Pfizer, Eli Lilly, MSD, Chugai Pharmaceutical, Nihon Medi-physics, Taiho Pharmaceutical, and Exact Sciences (with honoraria exceeding ¥500,000 from AstraZeneca, Daiichi Sankyo, Pfizer, Eli Lilly, MSD, and Chugai Pharmaceutical). Youichi Naito has received grants to his institution from AbbVie, Ono, Daiichi Sankyo, Taiho Pharmaceutical, Pfizer, Boehringer Ingelheim, Eli Lilly, Eisai, AstraZeneca, Chugai Pharmaceutical, Bayer, Takeda, Anthos Therapeutics, and Gilead Sciences; and has received consulting fees and honoraria for lectures and educational events from AstraZeneca, Eisai, Gilead Sciences, Eli Lilly, Novartis, Pfizer, Chugai Pharmaceutical, Taiho, Bayer, Daiichi Sankyo, MSD, Ono, Guardant, PDR Pharma, Nihon Kayaku, and Bristol Myers Squibb. Kazuki Nozawa has received consulting fees from Pfizer and Chugai Pharmaceutical, and honoraria for lectures and educational events from Daiichi Sankyo, Chugai Pharmaceutical, Eli Lilly, MSD, and Pfizer. Tadahiko Shien has received honoraria for lectures and educational events from AstraZeneca, Novartis, MSD, Eisai, Taiho Pharmaceutical, Gilead Sciences, Pfizer, Chugai Pharmaceutical, Daiichi Sankyo, Takeda, Kyowa Kirin, and Eli Lilly. Motonobu Ozaki has received honoraria from Pfizer, Daiichi Sankyo, Eli Lilly, and Chugai Pharmaceutical. The following authors declare no conflicts of interest: Tomomi Fujisawa, Toshiyuki Ishiba, Takehiko Sakai, Kazuki Sudo, Kaori Terada, Keita Sasaki, Noriko Mitome, Ryo Sadachi, and Taro Shibata.
